Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yellin

Showing results (521-530 of 625) with videos related to

Pageof 63
Sort By:
European Journal of Haematology|February 20, 2009
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimenJames R Berenson, Ori Yellin, Donald Woytowitz, et al.
Leukemia|February 23, 2012
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myelomaJ R Berenson, O Yellin, T Kazamel, et al.
Gut|March 7, 2013
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised studyLloyd Mayer, William J Sandborn, Yuriy Stepanov, et al.
AJR. American Journal of Roentgenology|December 25, 2014
An international multicenter comparison of time-SLIP unenhanced MR angiography and contrast-enhanced CT angiography for assessing renal artery stenosis: the renal artery contrast-free trialTimothy S E Albert, Masaaki Akahane, Isabelle Parienty, et al.
The Journal of Infectious Diseases|May 9, 2024
Humoral Correlates of Protection Against Influenza A/H3N2 Virus InfectionGregory Hoy, Daniel Stadlbauer, Angel Balmaseda, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|March 2, 2026
A Community-Informed Toolkit for Physician-Scientist Competencies and Milestones: Bridging the Worlds of Medicine and ResearchLourdes Estrada, Justin T Baca, Margaret H Baron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2007
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphomaStephen M Ansell, Steven M Horwitz, Andreas Engert, et al.
Therapeutic Drug Monitoring|June 1, 1992
Tissue concentrations of cefepime in acute cholecystitis patientsM P Okamoto, M A Gill, R K Nakahiro, et al.
Investigational New Drugs|January 19, 2010
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanomaEvan M Hersh, Steven J O'Day, John Powderly, et al.
Arthritis and Rheumatism|December 8, 2011
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritisMichael Yellin, Igor Paliienko, Andra Balanescu, et al.
Pageof 63

Showing results (521-530 of 625) with videos related to

Sort By:
Pageof 63
European Journal of Haematology|February 20, 2009
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimenJames R Berenson, Ori Yellin, Donald Woytowitz, et al.
Leukemia|February 23, 2012
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myelomaJ R Berenson, O Yellin, T Kazamel, et al.
Gut|March 7, 2013
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised studyLloyd Mayer, William J Sandborn, Yuriy Stepanov, et al.
AJR. American Journal of Roentgenology|December 25, 2014
An international multicenter comparison of time-SLIP unenhanced MR angiography and contrast-enhanced CT angiography for assessing renal artery stenosis: the renal artery contrast-free trialTimothy S E Albert, Masaaki Akahane, Isabelle Parienty, et al.
The Journal of Infectious Diseases|May 9, 2024
Humoral Correlates of Protection Against Influenza A/H3N2 Virus InfectionGregory Hoy, Daniel Stadlbauer, Angel Balmaseda, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|March 2, 2026
A Community-Informed Toolkit for Physician-Scientist Competencies and Milestones: Bridging the Worlds of Medicine and ResearchLourdes Estrada, Justin T Baca, Margaret H Baron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2007
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphomaStephen M Ansell, Steven M Horwitz, Andreas Engert, et al.
Therapeutic Drug Monitoring|June 1, 1992
Tissue concentrations of cefepime in acute cholecystitis patientsM P Okamoto, M A Gill, R K Nakahiro, et al.
Investigational New Drugs|January 19, 2010
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanomaEvan M Hersh, Steven J O'Day, John Powderly, et al.
Arthritis and Rheumatism|December 8, 2011
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritisMichael Yellin, Igor Paliienko, Andra Balanescu, et al.
Pageof 63